FY2025 Earnings Estimate for Cytokinetics Issued By B. Riley

Key Points

• B. Riley has revised its FY2025 earnings estimate for Cytokinetics, lowering it to an expected loss of $5.72 per share, down from a previous estimate of $5.62.
• The company reported quarterly earnings of ($1.12) EPS, surpassing the consensus estimate by $0.22 with significant revenue growth of 26727.3% year-over-year.
• Cytokinetics currently has a consensus rating of "Moderate Buy" among analysts, with an average price target of $75.71.

Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) - Equities researchers at B. Riley cut their FY2025 earnings per share (EPS) estimates for shares of Cytokinetics in a research note issued to investors on Monday, September 22nd. B. Riley analyst M. Mamtani now forecasts that the biopharmaceutical company will post earnings of ($5.72) per share for the year, down from their previous forecast of ($5.62). B. Riley currently has a "Buy" rating and a $80.00 target price on the stock. The consensus estimate for Cytokinetics' current full-year earnings is ($5.24) per share. B. Riley also issued estimates for Cytokinetics' Q4 2025 earnings at ($1.64) EPS, FY2026 earnings at ($6.04) EPS, FY2027 earnings at ($5.46) EPS, FY2028 earnings at ($3.39) EPS and FY2029 earnings at $0.21 EPS.

Cytokinetics (NASDAQ:CYTK - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.12) EPS for the quarter, topping the consensus estimate of ($1.34) by $0.22. The company had revenue of $66.77 million for the quarter, compared to analysts' expectations of $1.95 million. During the same quarter in the prior year, the firm earned ($1.31) EPS. The firm's revenue was up 26727.3% on a year-over-year basis.

Other research analysts have also issued research reports about the company. Evercore ISI lifted their price target on Cytokinetics from $60.00 to $80.00 and gave the stock an "outperform" rating in a report on Wednesday, September 3rd. Barclays lifted their price target on Cytokinetics from $53.00 to $71.00 and gave the stock an "overweight" rating in a report on Wednesday, September 3rd. Stifel Nicolaus lifted their price target on Cytokinetics from $87.00 to $96.00 and gave the stock a "buy" rating in a report on Tuesday, September 2nd. Raymond James Financial initiated coverage on Cytokinetics in a report on Wednesday, July 30th. They set a "market perform" rating on the stock. Finally, JPMorgan Chase & Co. cut their price objective on Cytokinetics from $71.00 to $53.00 and set an "overweight" rating for the company in a research report on Monday, June 9th. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $75.71.

Cytokinetics Stock Up 0.6%

NASDAQ CYTK opened at $48.55 on Wednesday. Cytokinetics has a 52 week low of $29.31 and a 52 week high of $59.39. The business's fifty day simple moving average is $41.19 and its 200-day simple moving average is $38.07. The firm has a market cap of $5.81 billion, a PE ratio of -9.52 and a beta of 0.62.

Insider Transactions at Cytokinetics

In other news, Director Edward M. Md Kaye sold 6,756 shares of the business's stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $50.00, for a total transaction of $337,800.00. Following the completion of the transaction, the director directly owned 23,230 shares of the company's stock, valued at approximately $1,161,500. The trade was a 22.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Robert I. Blum sold 5,000 shares of the business's stock in a transaction dated Monday, July 14th. The stock was sold at an average price of $38.15, for a total value of $190,750.00. Following the transaction, the chief executive officer directly owned 393,108 shares of the company's stock, valued at approximately $14,997,070.20. This represents a 1.26% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 33,756 shares of company stock valued at $1,452,550. 3.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Cytokinetics

Several institutional investors have recently added to or reduced their stakes in CYTK. GF Fund Management CO. LTD. purchased a new stake in Cytokinetics during the fourth quarter worth approximately $117,000. GAMMA Investing LLC lifted its stake in Cytokinetics by 15,210.5% during the first quarter. GAMMA Investing LLC now owns 45,013 shares of the biopharmaceutical company's stock worth $1,809,000 after purchasing an additional 44,719 shares during the last quarter. Parallel Advisors LLC lifted its stake in Cytokinetics by 500.5% during the first quarter. Parallel Advisors LLC now owns 1,099 shares of the biopharmaceutical company's stock worth $44,000 after purchasing an additional 916 shares during the last quarter. Mirador Capital Partners LP lifted its stake in Cytokinetics by 51.0% during the first quarter. Mirador Capital Partners LP now owns 99,125 shares of the biopharmaceutical company's stock worth $3,984,000 after purchasing an additional 33,489 shares during the last quarter. Finally, RFG Advisory LLC purchased a new stake in Cytokinetics during the first quarter worth approximately $1,286,000.

About Cytokinetics

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.